International: +1-347-960-6455
Ulcerative Colitis (UC) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

According to a new research report Ulcerative Colitis (UC) TherapeuticsPipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments published by Pharma Proff, UC therapeutics currently exhibits a proliferating pipeline with 50+ therapeutic candidates.

UC Therapeutics Pipeline Insights

Ulcerative colitis (UC) is a disease that affects colon or large intestine and results in inflammation of the colon and development of ulcers on intestinal linings. The disease is a result of improper functioning of immune system. As a repercussion, white blood cells (WBCs) reach the lining of large intestine, resulting in its inflammation. Signs of the disease usually are cramps in abdominal region, bloody stools, lose or urgent bowel movements, and others. The disease is non-contagious. Moreover, family history is a significant risk factor for the disease.

Treatment options for UC include infliximab, tofacitinib, aminosalicylate, corticosteroid, immunosuppressant, and ciclosporin for the reduction of inflammation. Surgery is the ultimate solution for the disease in extreme cases. The diagnosis of the disease is possible through physical examination and lab tests.

Xeljanz (Pfizer Inc.), Simponi and Remicade (Janssen Biotech Inc.), and Entyvio (Takeda Pharmaceuticals Company Limited) are some of the U.S. Food and Drug Administration (USFDA) approved drugs for the treatment for UC.

Insights into Pipeline Segments

According to the research findings, majority of the pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for UC through the oral route has shown promising results in clinical studies.

Positive Clinical Trial Results are Expected to Drive UC Therapeutics Pipeline

Companies that are involved in developing therapeutics for UC have shown positive clinical results in various phases of drug development. For instance, GW Pharmaceuticals plc, announced positive preliminary top-line results of phase IIa trial evaluating GWP42003 extract for treatment of UC in October 2014, which revealed that patients administered with the drug showed positive effects for UC.

Technological Advancements Play a Pivotal Role in UC Therapeutics Development

It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of UC therapeutics. For instance, Seres Therapeutics Inc. have developed microbiome technology to design specific therapies for particular diseases. For instance, the company developed Ecobiotic drugs for the treatment of UC.

Browse Detailed Report at:

Global Market for UC Therapeutics is Expected to Increase Statistically in the next 10 years

Xeljanz, Simponi, Remicade, and Entyvio are some of the approved drugs for the treatment of UC. These drugs hold significant share in the global UC therapeutics market. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall UC therapeutics market is expected to grow significantly in the upcoming years.

Some of the key players involved in the development of UC therapeutics are Pfizer Inc., Takeda Pharmaceutical Company Limited, Seres Therapeutics Inc., Janssen Biotech Inc., Receptos Inc., EA Pharma Co. Ltd., Celgene Corporation, and InDex Pharmaceuticals AB.

UC Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of UC. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the UC therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to UC.